The importance of cardiovascular autonomic neuropathy (CAN) is underappreciated, and there is no standardised treatment protocol. The purpose of this study was to see how benfotiamine (BFT) affected heart rate variability (HRV) in individuals with T2DM and CAN. A total of 32 people with T2DM with confirmed CAN were randomly allocated to one of two treatment groups: BFT 300 mg/d was given to Group 2 (n=17) in addition to their regular antihyperglycemic medication for three months. Heart rate variability (HRV) parameters were investigated. BFT was shown to increase the sum of squares of variations between consecutive normal-to-normal intervals, as well as the high-frequency component of HRV, throughout both active and inactive sections of the day. BFT's positive outcomes imply that it might be used to treat persons who have T2DM and a confirmed stage of CAN.
Victoria A. Serhiyenko,
Department of Endocrinology, Danylo Halytsky Lviv National Medical University, 79010, Lviv, Ukraine.
Marta E. Hotsko,
Department of Endocrinology, Danylo Halytsky Lviv National Medical University, 79010, Lviv, Ukraine.
Alexandr Serhiyenko,
Department of Endocrinology, Danylo Halytsky Lviv National Medical University, 79010, Lviv, Ukraine.
Please see the link here: https://stm.bookpi.org/CAPRV-3/article/view/6945
No comments:
Post a Comment